Oct 20, 2020 / 06:00PM GMT
Patrick Ralph Trucchio - H.C. Wainwright & Co, LLC, Research Division - MD of Equity Research & Senior Healthcare Analyst
Hi. Good afternoon, everyone, and welcome back for our next session this afternoon. We have VBI Vaccines presenting. And from VBI, we have Jeff Baxter, President and CEO; and Dave Anderson, Chief Scientific Officer, from VBI Vaccines.
Jeffrey R. Baxter - VBI Vaccines Inc. - President, CEO & Director
Great. Patrick, thanks very much for the introduction. And also, thank you, Patrick, and to everyone at H.C. Wainwright for including us today. And I must say, watching the sessions, it's been a great meeting. So congratulations.
If we can just skip to the next slide, please. So after customary forward-looking statements, this is VBI's hepatitis B portfolio. And we're really excited about the opportunity this affords us in both the prophylactic and the therapeutic space.
Just a moment of history, back in 2016, VBI acquired a public -- a privately held Israeli biotech company who had this incredibly successful potent
VBI Vaccines Inc. - Special Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot